12:00 AM
 | 
May 13, 2013
 |  BC Week In Review  |  Company News  |  Other News

ChronTech infectious, drug delivery news

ChronTech said that a group of shareholders offered to acquire all assets related to ChronTech's development programs for DNA vaccines against HBV and HCV for $1 million. The shareholders have formed newco Avac Pharma Ltd. for the transfer....

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >